|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Sixty-two soft tissue sarcoma samples were investigated for the presence of p53 mutations and for p53 immunoreactivity.
|
8630896 |
1995 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
APC mutated (Min) mice develop large and small bowel adenomas, a small proportion of which, in time, become malignant. p53 deficient mice develop predominantly lymphoma and sarcoma.
|
7478622 |
1995 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Amplification of the MDM2 gene, which maps to chromosome band 12q13 and encodes a p53-binding protein, may result in functional inactivation of p53 and has been observed in various bone and soft tissue sarcomas.
|
7738717 |
1995 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
These data show that approximately 20% of sarcomas harbour TP53 gene alterations and illustrate a variety of TP53 gene mutation types.
|
7640047 |
1995 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
For 64 cases the results were concordant: 56 sarcomas were considered to have wild-type p53 by both techniques.
|
8821948 |
1996 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Germline mutations in the p53 tumor suppressor gene are associated with the Li-Fraumeni syndrome, characterized by childhood sarcoma, leukemia and early onset breast cancer and has occasionally been found also in familial breast-ovarian cancer.
|
8710380 |
1996 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Recently, mutations in the P53 gene were found to confer resistance to anthracyclines in a mouse sarcoma tumor model, and overexpression of the p53 protein (which, in most cases, is due to a mutated gene) was found to be associated with lack of response to cisplatin-based chemotherapy in non-small cell lung cancer.
|
8673929 |
1996 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Prognosis is correlated with p53 mutation type for soft tissue sarcoma patients.
|
8797580 |
1996 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Our results also suggest that p53 status does not directly affect the expression of bcl-2 in sarcomas.
|
8834522 |
1996 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Our results and those of others suggest p53 codon 245 as a mutational hotspot in sarcomas, as recognized in carcinomas.
|
8797875 |
1996 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
p53 gene mutations in soft-tissue sarcomas--correlations with p53 immunohistochemistry and DNA ploidy.
|
9177493 |
1997 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Mutation of the p53 tumor suppressor gene, with resultant overexpression of p53 protein, frequently occurs in human soft tissue sarcomas, supporting the role of p53 mutations in the pathogenesis of soft tissue sarcoma and the possible usefulness of p53 immunolocalization as a screening method for p53 mutations.
|
9140310 |
1997 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
The emergence of genetic alterations as prognostic factors, as illustrated by Ewing's family of tumors, osteosarcoma, and p53 expression in soft tissue sarcomas in general, is discussed.
|
9251884 |
1997 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The analysis of 475 tumors in 91 families with p53 germline mutations reported since 1990 shows that breast carcinomas are most frequent (24.0%), followed by bone sarcomas (12.6%), brain tumors (12.0%), and soft tissue sarcomas (11.6%).
|
9006316 |
1997 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
The mutation spectrum and frequency in exon 7 of the p53 gene are discussed with respect to oncogenesis in soft tissue sarcomas.
|
9504819 |
1997 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
A tumorigenic connection between the oncogene product Mdm2 and tumor suppressor p53 is generally accepted, but their possible clinical relevance has not yet been investigated sufficiently in soft tissue sarcoma.
|
9528860 |
1998 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Molecular assessment of clonality leads to the identification of a new germ line TP53 mutation associated with malignant cystosarcoma phyllodes and soft tissue sarcoma.
|
10207667 |
1998 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
These effectors were cross-reactive against sarcomas expressing p53 missense mutations outside of the p53(232-240) epitope, but not within it.
|
9419445 |
1998 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
The p53 gene in soft tissue sarcomas: prognostic value of DNA sequencing versus immunohistochemistry.
|
9568075 |
1998 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Compared with other highly malignant mesenchymal pediatric tumors such as osteosarcomas, mutations of p53 and ras in Ewing's sarcomas are an extraordinarily rare event.
|
9587933 |
1998 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
The transgenic mice are predisposed to spontaneous tumor formation, and the incidence of sarcomas observed in the Mdm2-transgenic mice in the presence or absence of functional p53 demonstrates that, in addition to Mdm2-mediated inactivation of p53, there exists a p53-independent role for Mdm2 in tumorigenesis.
|
9861017 |
1998 |
|
Sarcoma
|
1.000 |
Biomarker
|
group |
BEFREE |
The ability to restore wt p53 growth-regulatory functions in soft-tissue sarcoma may ultimately be useful as a future therapy in patients with soft-tissue sarcomas.
|
9717829 |
1998 |
|
Sarcoma
|
1.000 |
AlteredExpression
|
group |
BEFREE |
Telomerase activity of sarcoma cell lines and fibroblasts is independent of p53 status.
|
9626480 |
1998 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
In this study we examined 63 methylcholanthrene (MCA)-induced sarcomas from C57BL/6N x C3H/HeN F1 (BCF1) or C3H/HeN x C57BL/6N F1 (CBF1) mice for p53 gene mutations and loss of heterozygosity (LOH) of chromosome 11.
|
9600120 |
1998 |
|
Sarcoma
|
1.000 |
GeneticVariation
|
group |
BEFREE |
Collectively, these findings indicate that radiation is causative for soft tissue sarcomas via p53 gene mutations.
|
9645763 |
1998 |